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metastasis
The spatial conformation and the poor prognosis of perito-
neal metastases (PM) make it an original entity. Once contam-
inated by tumour cells, disease spread is rapid and
multidirectional over a surface that is equal to the body sur-
face area in m2. The prognosis of PM is poorer than that of
metastatic spread elsewhere; patients with colorectal metas-
tases treated with chemotherapy and targeted therapies have
a median survival of 15 months with PM versus 21 months
without PM (P < 0.001) [1]. The presence of PM is thus tradi-
tionally deemed a fatal event.
Complete cytoreductive surgery (CCRS) resects all visible
peritoneal deposits, and the remaining invisible disease is
subsequently treated with a high local concentration of che-
motherapy potentiated by hyperthermia (HIPEC) in one ses-
sion. This aggressive surgery can therefore be proposed only
for disease confined to the peritoneum. According to the ori-
gin of the disease, such treatment is administered in two out
of three colorectal carcinomas, one out of three gastric carci-
nomas, seven out of ten ovarian carcinomas, nine out of ten
pseudomyxomas and eight out of ten mesotheliomas.
2. Aggressive surgery as a state of the art:
pseudomyxoma and mesothelioma
CCRS + HIPEC is considered the gold standard treatment for
these two peritoneal malignancies. In a retrospective multi-
centric registry, including 2298 patients with pseudomyxoma
from 16 specialised units using this combined approach [2],
median survival was 16.3 years and 10-year survival was
63%. Mortality was 2%, and major complications occurred in
24%. The main prognostic factors in the multivariate analysis
were the histological subtype, a high extent score and no HI-
PEC. CCRS achieved the best outcome. Similar conclusions
were drawn for malignant mesothelioma in a multi-institu-
tional registry including 405 patients [3] in which only 46%
underwent CCRS. Median survival was 53 months and 5-year
survival was 47%.3. Aggressive surgery as a new therapeutic
approach: colorectal carcinoma
3.1. Long-term results after CCRS plus HIPEC
Ten years ago the results of a randomised study [4] – which in-
cluded 105 patients treated for colorectal PM (systemic che-
motherapy versus with surgery plus HIPEC) – demonstrated
significantly prolonged survival in patients treated with sur-
gery plus HIPEC, with a median survival twofold higher
(P = 0.03), although CCRS was achieved in only 38% of cases.
This was confirmed in another study [5] comparing two sim-
ilar groups in terms of the main patient characteristics. All
patients underwent a laparotomy and had resectable PM; 48
patients were treated with CCRS + HIPEC in one centre, and
48 were treated in five other centres without HIPEC. After a
minimal follow-up of 63 months, 5-year overall survival was
51% in the CCRS + HIPEC group and 13% for patients in the
no-HIPEC group (P < 0.05).
Long-term results of primary CCRS + HIPEC demonstrated
that definitive cure of PM was possible in 16% of the 93 pa-
tients treated between 1995 and 2004 [6], a rate which is close
to that obtained with a similar long follow-up after hepatec-
tomy for liver metastases (LM). Median survival was
36 months at that time, but attained 48 months in 2011 [7],
emphasising a learning-curve effect and better patient
selection.
CCRS + HIPEC is wrongly reputed to cause excessive mor-
bidity, but in specialised centres and in selected patients mor-
tality is lower than 5% and grade 3–4 morbidity is lower than
30%.
Aggressive surgery plus HIPEC is also considered costly,
but its clear superiority over the usual palliative therapies in
terms of QALY (cost-efficacy) has been demonstrated.
Regarding prognostic factors, the results of the French Reg-
istry – which analysed 523 patients treated with CCRS + HIPEC
– showed that the extent of PM (scored with the peritoneal
cancer index, PCI) is the main prognostic factor [8]. There
were no survivors when the PCI exceeded 20, and we now
consider a PCI above 20 to be a contraindication.
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No randomised study has compared CCRS to systemic che-
motherapy. The results of four retrospective series provide
some elements of response: median survival was 28 months,
with 5-year survival at 24%, showing clear but limited superi-
ority over systemic chemotherapy alone. In contrast, an
incomplete resection (R2) afforded no advantage, with sur-
vival rates similar to those reported with chemotherapy alone
[8]. In conclusion, CCRS benefits patients with limited PM and
a good general status.
3.3. Role of hyperthermic intraperitoneal chemotherapy
No randomised study has been published to date. We are
awaiting the results of Prodige 7, the French randomised trial
comparing the survival of patients treated with CCRS + HIPEC
to that of patients treated with CCRS alone, whose accrual
was recently completed (n = 260). This study will define the
real impact of HIPEC.
3.4. Future
As this aggressive surgery gives far better results for limited
PM, it should be used mainly to treat patients at a very early
stage, but early diagnosis of PM cannot be done by clinical
or imaging examinations. Only systematic second-look sur-
gery (SLS) can detect PM early, but this aggressive approach
should be proposed exclusively in patients at high risk of
PM. In such patients (limited PM resected with the primary,
a history of ovarian metastases and a perforated primary tu-
mour) with no preoperative evidence of PM, SLS has allowed
us to find macroscopic PM in 55% of cases [9], and to treat
PM earlier with CCRS + HIPEC. A randomised multicentric
trial (Prophylochip) comparing the standard treatment (fol-
low-up) in these high-risk patients to the new one (second-
look + HIPEC) is ongoing.
4. CCRS + HIPEC to treat PM of other origins
Indications are in progress for ovarian-, gastric-, NET- and
rare disease-derived PM. The initial results of CCRS + HIPEC
were disappointing, but progress in techniques and in indica-
tions in ongoing prospective trials is giving promising results.
5. Conclusion
CCRS + HIPEC yields long-term survival in patients with PM.
No clear and widely accepted definition of resectable PM ex-
ists. However, we postulate that when the patient has a goodgeneral status and when the extent of PM is limited, without
extraperitoneal disease, this approach is beneficial.
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